Quantification of Her-2/Neu Gene in Breast Cancer Patients using Real Time-Polymerase Chain Reaction (Q-PCR) and Correlation with Immunohistochemistry Findings
| Autor: | Naqiyah Ibrahim, Rosniza Muhammmad Hussain, Sharifah Noor Akmal Syed Hussain, Zuraini Abdul Razak, Norlia Abdullah, Clarence Ko Ching Huat, Siti Aishah Md Ali, Nor Azian Abdul Murad, A. Rahman A. Jamal, Rohaizak Muhammad |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Cancer Research Receptor ErbB-2 Epidemiology medicine.medical_treatment Breast Neoplasms Biology Real-Time Polymerase Chain Reaction Proto-Oncogene Mas Immunoenzyme Techniques Pathogenesis Breast cancer Gene duplication Biomarkers Tumor medicine Humans Breast Gene Aged Growth factor Gene Amplification Public Health Environmental and Occupational Health DNA Middle Aged Prognosis medicine.disease Molecular biology Real-time polymerase chain reaction Oncology Immunohistochemistry Female Tyrosine kinase |
| Zdroj: | Asian Pacific Journal of Cancer Prevention. 14:1655-1659 |
| ISSN: | 1513-7368 |
| DOI: | 10.7314/apjcp.2013.14.3.1655 |
| Popis: | Background: HER-2/neu is a proto-oncogene that encodes a transmembrane tyrosine kinase growth factor which is crucial for stimulating growth and cellular motility. Overexpression of HER-2/neu is observed in 10-35% of human breast cancers and is associated with pathogenesis, prognosis as well as response to therapy. Given the imperative role of HER-2/neu overexpression in breast cancer, it is important to determine the magnitude of amplification which may facilitate a better prognosis as well as personalized therapy in affected patients. In this study, we determined HER-2/neu protein expression by immunohistochemistry (IHC) concurrently with HER-2/neu DNA amplification by quantitative real time-polymerase chain reaction (Q-PCR). Materials and Methods: A total of 53 paired tissue samples from breast cancer patients were frozen-sectioned to characterize the tumour and normal tissues. Only tissues with 80% tumour cells were used in this study. For confirmation, Q-PCR was used to determine the HER-2/neu DNA amplification. Results: We found 20/53 (37.7%) of the tumour tissues to be positive for HER-2/neu protein overexpression using IHC. Out of these twenty, only 9/53 (17%) cases were in agreement with the Q-PCR results. The concordance rate between IHC and Q-PCR was 79.3%. Approximately 20.7% of positive IHC cases showed no HER-2/neu gene amplification using Q-PCR. Conclusion: In conclusion, IHC can be used as an initial screening method for detection of the HER-2/neu protein overexpression. Techniques such as Q-PCR should be employed to verify the IHC results for uncertain cases as well as determination of HER-2/neu gene amplification |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|